Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center
Articles
Decision Factors for SubQ Therapy and Unmet Needs
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center;Vijayakrishna Gadi, MD, University of Illinois College of Medicine;William Gradishar, MD, Northwestern Medicine;Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
March 5th 2021Read More
Phase 3 FeDeriCa and PHranceSCa Trial Overviews
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center;Vijayakrishna Gadi, MD, University of Illinois College of Medicine;William Gradishar, MD, Northwestern Medicine;Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
February 26th 2021Read More
Novel Agents for Late-Stage HER2+ MBC
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center;Vijayakrishna Gadi, MD, University of Illinois College of Medicine;William Gradishar, MD, Northwestern Medicine;Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
February 26th 2021Read More
Practical Advice for Toxicity Management in HER2+ MBC
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center;Vijayakrishna Gadi, MD, University of Illinois College of Medicine;William Gradishar, MD, Northwestern Medicine;Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
February 19th 2021Read More
Brain Metastases Therapy in Second-Line HER2+ MBC
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center;Vijayakrishna Gadi, MD, University of Illinois College of Medicine;William Gradishar, MD, Northwestern Medicine;Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
February 19th 2021Read More
Sequencing Therapy in R/R HER2+ MBC
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center;Vijayakrishna Gadi, MD, University of Illinois College of Medicine;William Gradishar, MD, Northwestern Medicine;Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
February 12th 2021Read More
Newly FDA Approved Therapies: R/R HER2+ MBC
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center;Vijayakrishna Gadi, MD, University of Illinois College of Medicine;William Gradishar, MD, Northwestern Medicine;Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
February 12th 2021Read More
Moving Metastatic Therapy to Early Stage Setting
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center;Vijayakrishna Gadi, MD, University of Illinois College of Medicine;William Gradishar, MD, Northwestern Medicine;Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
February 5th 2021Read More
Hormone Therapy in HER2+ Breast Cancer
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center;Vijayakrishna Gadi, MD, University of Illinois College of Medicine;William Gradishar, MD, Northwestern Medicine;Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
February 5th 2021Read More
De-Escalation of Adjuvant Anti-HER2 Therapy and Chemo
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center;Vijayakrishna Gadi, MD, University of Illinois College of Medicine;William Gradishar, MD, Northwestern Medicine;Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
January 29th 2021Read More
Adjuvant Systemic Therapy Data Updates
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center;Vijayakrishna Gadi, MD, University of Illinois College of Medicine;William Gradishar, MD, Northwestern Medicine;Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
January 29th 2021Read More
Adjuvant Systemic Therapy Decision Factors
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center;Vijayakrishna Gadi, MD, University of Illinois College of Medicine;William Gradishar, MD, Northwestern Medicine;Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
January 20th 2021Read More
HR-/HER2+ Early Stage Breast Cancer: Standards of Care
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center;Vijayakrishna Gadi, MD, University of Illinois College of Medicine;William Gradishar, MD, Northwestern Medicine;Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
January 20th 2021Read More
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
HER2+ MBC Adverse-Event Management
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
After Progression on PIK3CAi Therapy: MTOR Inhibition
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
Significance of PIK3CA Mutation in HR+ Breast Cancer
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
Mechanisms of Resistance to CDK4/6 Inhibitors
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
CDK4/6 Clinical Trial Survival Data Impact
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
CDK4/6 Inhibition in HR+ Metastatic Breast Cancer
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
Next-Generation Sequencing: Triple Negative Breast Cancer
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
Phase 3 ASCENT Regimen Accelerated Approval
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
SWOG S1416 and TBCRC 048 Phase 2 Trial Overviews
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
ASCO New Data: PARP Inhibitors
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
KEYNOTE-355 Regimen’s Role in Treatment Paradigm
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
PD-L1 Testing Standard of Practice
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
Perspectives on Recent Progress: Program Overview
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
Latest Updated Articles
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
